# 2025年12月22日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 病毒感染与血脑屏障：分子研究洞见与治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41020593)
**期刊：** The Journal of infectious diseases
**PMID：** 41020593
**DOI：** 10.1093/infdis/jiaf455

### 第一部分 原文与翻译

**英文原标题：** Viral Infection and the Blood-Brain Barrier: Molecular Research Insights and Therapies.

> **英文摘要：**
> The blood-brain barrier (BBB) protects the brain from pathogenic microorganisms. Neurologic complications from viral infections, including herpes simplex virus, varicella zoster virus, HIV, Japanese encephalitis virus, and SARS-CoV-2, are linked to BBB dysfunction and loss of barrier integrity. Increased BBB permeability associated with viral infections can occur through several mechanisms, such as direct neurotropism, Trojan horse mechanisms, or systemic infection and inflammation. Viruses cause direct and indirect immune-mediated damage. Understanding these neuroimmune mechanisms is critical to establish therapeutic strategies to protect BBB function. This review describes the effect of viral infection on the BBB, clinical methods to assess BBB integrity, and clinical management approaches to address viral-induced BBB damage.

> **中文摘要：**
> 血脑屏障（BBB）保护大脑免受病原微生物的侵袭。病毒感染引起的神经系统并发症，包括单纯疱疹病毒、水痘带状疱疹病毒、HIV、日本脑炎病毒及SARS-CoV-2等，与BBB功能障碍及屏障完整性丧失有关。与病毒感染相关的BBB通透性增加可通过多种机制发生，如直接的神经向性、“特洛伊木马”机制或系统性感染与炎症。病毒可导致直接及间接的免疫介导性损伤。理解这些神经免疫机制对于建立保护BBB功能的治疗策略至关重要。本综述描述了病毒感染对BBB的影响、评估BBB完整性的临床方法，以及应对病毒诱导BBB损伤的临床管理途径。

### 第二部分 AI 大师评价

该综述旨在系统阐述病毒感染对血脑屏障的破坏机制及其临床意义，通过机制层面分析神经向性、免疫介导性及系统性炎症的作用路径，强调了神经免疫互作的重要性。文章整合了多种病毒（如HSV、HIV、SARS-CoV-2等）的典型研究进展，突出了跨学科防治策略的必要性。其创新点在于将分子机制与临床管理相结合，为神经感染病变的干预提供了生物学基础，但仍需更多实验及临床数据验证具体治疗方法的可行性。

---

## 2. 普通感冒与对 SARS-CoV-2 感染的保护相关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40795882)
**期刊：** The Journal of infectious diseases
**PMID：** 40795882
**DOI：** 10.1093/infdis/jiaf374

### 第一部分 原文与翻译

**英文原标题：** The Common Cold Is Associated With Protection From SARS-CoV-2 Infections.

> **英文摘要：**
> BACKGROUND: Adults and children often respond differently to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, with adults facing a higher risk of symptomatic and severe illness. We hypothesize that children's protection from symptomatic SARS-CoV-2 may be due to more frequent respiratory viral infections, which prime their airway antiviral defenses.
> 
> METHODS: Using case-cohort and case-control analyses in the Human Epidemiology and Response to SARS-CoV-2 cohort, we evaluated whether infection with common respiratory viruses protects against SARS-CoV-2 infections and investigated airway molecular mechanisms by which this protection is achieved. We tested 10 493 longitudinal nasal swabs from 1156 participants for 21 respiratory pathogens. We performed RNA sequencing on 147 swabs (n = 144 participants) collected prior to SARS-CoV-2 infection and 391 swabs (n = 165 participants) during and before rhinovirus infection.
> 
> RESULTS: Participants with rhinovirus infection in the previous 30 days were at 48% lower risk of SARS-CoV-2 infection (adjusted hazard ratio, 0.52; P = .034). Among participants with SARS-CoV-2 infection, recent rhinovirus infection was associated with 9.6-fold lower SARS-CoV-2 viral load (P = .0031). Higher preinfection expression of 57 genes was associated with lower SARS-CoV-2 viral load, including 24 antiviral defense genes; 22 of these were induced by rhinovirus infections. Relative to adults, children expressed higher levels of the antiviral gene signature (P = .014) and were at 2.2-fold increased risk for rhinovirus infections.
> 
> CONCLUSIONS: Rhinovirus infections, which trigger increased expression of antiviral airway genes, are linked to a lower risk of SARS-CoV-2 infection. Frequent rhinovirus infections may enhance this protective gene profile, partially explaining why children experience milder SARS-CoV-2 infections compared to adults.
> 
> CLINICAL TRIALS REGISTRATION: NCT04375761.

> **中文摘要：**
> 背景：成年人和儿童对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的反应常常不同，成年人面临更高的症状性和重症疾病风险。我们假设，儿童对症状性SARS-CoV-2感染的保护可能源于他们更频繁的呼吸道病毒感染，从而预激其气道抗病毒防御机制。
> 
> 方法：我们在“人类流行病学与SARS-CoV-2应答队列”中采用病例队列和病例对照分析，评估常见呼吸道病毒感染是否可对SARS-CoV-2感染起保护作用，并探讨这种保护作用的气道分子机制。我们检测了来自1156名参与者的10,493份纵向鼻拭子样本，以筛查21种呼吸道病原体。我们还对147份（n=144名参与者，采集于SARS-CoV-2感染前）和391份（n=165名参与者，采集于鼻病毒感染前及感染期间）的鼻拭子样本进行了RNA测序。
> 
> 结果：在过去30天内感染鼻病毒的参与者，其SARS-CoV-2感染风险降低了48%（校正风险比0.52；P=0.034）。在感染SARS-CoV-2的参与者中，近期鼻病毒感染者的SARS-CoV-2病毒载量低9.6倍（P=0.0031）。57个基因的较高感染前表达与较低的SARS-CoV-2病毒载量相关，其中包括24个抗病毒防御相关基因；其中有22个基因由鼻病毒感染诱导。与成年人相比，儿童抗病毒基因特征表达水平更高（P=0.014），且其感染鼻病毒的风险增加了2.2倍。
> 
> 结论：鼻病毒感染可诱导气道抗病毒基因的上调表达，并与较低的SARS-CoV-2感染风险相关。频繁的鼻病毒感染可能强化这种保护性基因特征，部分解释了儿童相比成年人为何经历更轻症的SARS-CoV-2感染。
> 
> 临床试验注册号：NCT04375761。

### 第二部分 AI 大师评价

本研究通过大规模人群队列分析与分子水平检测，探讨了普通呼吸道病毒感染（尤其是鼻病毒）对SARS-CoV-2感染风险的影响。结果显示，近期鼻病毒感染可显著降低SARS-CoV-2感染率与病毒载量，其机制与气道抗病毒基因的上调有关。研究首次在人群层面证实鼻病毒与抗SARS-CoV-2防御之间的关联，为儿童较轻症COVID-19提供了生物学解释。该研究具有创新性的免疫交互视角，但因观察性设计仍需进一步实验验证。

---

## 3. 非人灵长类细菌性脓毒症模型中低密度中性粒细胞内脾酪氨酸激酶的升高

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40747802)
**期刊：** The Journal of infectious diseases
**PMID：** 40747802
**DOI：** 10.1093/infdis/jiaf403

### 第一部分 原文与翻译

**英文原标题：** Elevated Spleen Tyrosine Kinase in Low-Density Neutrophils During Bacterial Sepsis in a Nonhuman Primate Model.

> **英文摘要：**
> BACKGROUND: Sepsis is a leading cause of death worldwide. Identifying novel host-directed therapeutic targets may improve sepsis outcomes.
> 
> METHODS: Six nonhuman primates were infected with Klebsiella pneumoniae to induce septic shock and provided supportive care for up to 72 hours. Flow cytometry was used to characterize whole-blood neutrophils (WBNs) and low-density neutrophils (LDNs) at time 0 (T0), T6, T24, and T48 hours postinfection, and postmortem examination (ie, necropsy). Dimensional reduction with clustering via FlowSOM and traditional gating strategies were used to compare WBNs to LDNs and delineate spleen tyrosine kinase (SYK) expression across neutrophils subsets. We measured soluble biomarkers of end-organ dysfunction and neutrophil activation, and quantified SYK and myeloperoxidase in tissue.
> 
> RESULTS: At T6, we identified populations of active immature WBNs and a population of LDNs not detected at baseline. At T24, neutrophil heterogeneity increased across WBNs and LDNs with differential expression of myeloperoxidase (MPO). Compared to WBNs, LDNs were more activated with increased MPO expression. At T6, SYK expression surged in WBNs and LDNs and SYK+ WBNs and LDNs expressed higher levels of MPO and lactoferrin compared to SYK- neutrophils. Circulating levels of SYK+ LDNs significantly correlated with serum creatinine levels, indicative of acute kidney injury; prolonged prothrombin time and decreased fibrinogen, indicative of consumptive coagulopathy; and SYK expression in tissues.
> 
> CONCLUSIONS: Bacterial sepsis leads to heterogenous populations of circulating neutrophils, including LDNs. Elevated SYK expression in WBNs and LDNs correlates with end-organ dysfunction, highlighting SYK as a potential therapeutic target in bacterial sepsis.

> **中文摘要：**
> 背景：脓毒症是全球主要的死亡原因之一。鉴定新的宿主导向治疗靶点可能改善脓毒症的预后。
> 
> 方法：将六只非人灵长类动物感染肺炎克雷伯菌以诱导感染性休克，并在最长72小时内给予支持治疗。采用流式细胞术在感染后0小时（T0）、6小时（T6）、24小时（T24）和48小时（T48）以及尸检时，对全血中性粒细胞（WBNs）和低密度中性粒细胞（LDNs）进行表型分析。利用FlowSOM的降维聚类算法和传统门控策略比较WBNs与LDNs的差异，并描绘脾酪氨酸激酶（SYK）在中性粒细胞亚群中的表达。我们测定了与器官功能障碍及中性粒细胞活化相关的可溶性生物标志物，并定量检测组织中SYK与髓过氧化物酶（MPO）的表达。
> 
> 结果：在T6时，检测到活跃的未成熟WBN亚群和基线未发现的LDNs。至T24时，WBNs与LDNs的中性粒细胞异质性增加，并表现出MPO表达的差异。与WBNs相比，LDNs更为活化，MPO表达更高。T6时，WBNs与LDNs中的SYK表达显著上升，SYK阳性（SYK+）WBNs与LDNs较SYK阴性（SYK−）中性粒细胞具有更高的MPO和乳铁蛋白表达。循环中SYK+ LDNs水平与血清肌酐升高显著相关（提示急性肾损伤）、凝血酶原时间延长及纤维蛋白原下降（提示消耗性凝血功能障碍），并与组织中SYK表达呈相关。
> 
> 结论：细菌性脓毒症可导致循环中中性粒细胞群体的异质性增加，其中包括LDNs。WBNs与LDNs中SYK表达升高与器官功能障碍相关，提示SYK可能是细菌性脓毒症的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究基于非人灵长类细菌性脓毒症模型，通过流式细胞分析深入探索了低密度和全血中性粒细胞在败血症过程中的异质性与SYK信号变化。结果显示，SYK在两类中性粒细胞中均显著升高，并与多器官损伤相关的生物标志物密切关联，提示其在脓毒症发病机制中具有关键作用。研究创新性地揭示了SYK与中性粒细胞亚型功能状态之间的动态联系，但样本量有限且为动物模型，需在人类研究中进一步验证。

---

## 4. 耐甲氧西林金黄色葡萄球菌菌血症复发表现出多样的基因组特征，但在菌血症相关基因上呈现趋同。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40709822)
**期刊：** The Journal of infectious diseases
**PMID：** 40709822
**DOI：** 10.1093/infdis/jiaf352

### 第一部分 原文与翻译

**英文原标题：** Methicillin-Resistant Staphylococcus aureus Bacteremia Relapses Show Diverse Genomic Profiles but Convergence in Bacteremia-Associated Genes.

> **英文摘要：**
> BACKGROUND: Recurrence of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a high risk complication for patients. Distinguishing persistent lineages from new infections is not standardized across clinical studies.
> 
> METHODS: We investigated factors contributing to recurrence of MRSA bacteremia among subjects in Philadelphia, Pennsylvania. Subject demographics and clinical history were collected and paired with whole-genome sequences of infection isolates. Recurrent bacteremia episodes were recorded and defined as relapse infections (same lineage) or new infections by genomic criteria, where a relapse contained isolates ≤ 25 single nucleotide polymorphisms (SNP) different, and by clinical criteria. All isolates were assessed for pairwise SNP distances, common mutations, and signatures of within-host adaptation using the McDonald-Kreitman test. Clusters of transmission between relapse-associated isolates and other subject lineages were identified.
> 
> RESULTS: Among 411 sequential subjects with MRSA bacteremia, 32 experienced recurrent bacteremia episodes, with 24 subjects having exclusively relapse infections, 6 with infections exclusively from a new strain, and 2 patients with both relapse and new infections. No concordance between a genomic and a clinical definition of relapse was evident (Cohen κ = 0.18; confidence interval, -0.41). Recurrence-associated lineages exhibited signatures of positive selection (G test, < 0.01). Genes with SNPs occurring in multiple relapse lineages have roles in antibiotic resistance and virulence, including 5 lineages with mutations in mprF and 3 lineages with mutations in rpoB, which corresponded with evolved phenotypic changes in daptomycin and rifampin resistance.
> 
> CONCLUSIONS: Recurrent infections have a diverse strain background. Relapses can be readily distinguished from newly acquired infections using genomic sequencing but not clinical criteria.

> **中文摘要：**
> 背景：耐甲氧西林金黄色葡萄球菌（MRSA）菌血症复发是患者的一种高风险并发症。在临床研究中，用于区分持续感染株与新感染的标准尚未统一。
> 
> 方法：我们研究了导致宾夕法尼亚州费城地区受试者MRSA菌血症复发的因素。收集受试者的人口学特征和临床病史，并将其与感染分离株的全基因组序列配对。记录复发性菌血症事件，并根据基因组标准定义为复发感染（同一系统发育谱系）或新感染，其中复发感染的菌株间单核苷酸多态性（SNP）差异≤25个，并同时依据临床标准进行分类。对所有分离株进行成对SNP距离、常见突变及宿主体内适应性特征分析，采用McDonald-Kreitman检验。识别与复发相关的分离株与其他个体谱系之间的传播簇。
> 
> 结果：在411名连续MRSA菌血症受试者中，32名出现复发性菌血症事件，其中24名仅发生复发感染，6名仅感染新菌株，另有2名患者同时存在复发与新感染。基因组定义与临床定义的复发无一致性（Cohen κ = 0.18；置信区间为 -0.41）。与复发相关的菌株表现出正选择信号（G检验，P < 0.01）。在多个复发谱系中出现SNP的基因主要涉及抗生素耐药性和毒力，包括5个谱系中mprF基因突变和3个谱系中rpoB基因突变，这些突变与达托霉素和利福平耐药性的表型演变相关。
> 
> 结论：复发性感染具有多样的菌株背景。利用基因组测序可清晰区分复发感染与新获得感染，但临床标准无法实现这一区分。

### 第二部分 AI 大师评价

本研究旨在通过基因组学方法探讨MRSA菌血症复发的分子特征与机制。研究结合临床资料与全基因组测序，明确区分复发感染与新感染，并揭示了复发相关菌株存在正向选择压力。发现mprF与rpoB突变与耐药性增强有关，提示宿主体内适应性演化的重要性。该研究在菌血症复发分型方面具有创新性，但临床-基因组定义不一致也反映出现有临床判定标准的局限。

---

## 5. 难治性肠球菌菌血症的临床与基因组特征：一项多中心前瞻性队列研究（VENOUS）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40629152)
**期刊：** The Journal of infectious diseases
**PMID：** 40629152
**DOI：** 10.1093/infdis/jiaf358

### 第一部分 原文与翻译

**英文原标题：** Clinical and Genomic Characterization of Recalcitrant Enterococcal Bacteremia: A Multicenter Prospective Cohort Study (VENOUS).

> **英文摘要：**
> BACKGROUND: Patients with recalcitrant enterococcal bloodstream infections are at greater risk of adverse outcomes. We identified patients in the 2016-2022 Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS) cohort experiencing recalcitrant bloodstream infections for further clinical and genomic characterization.
> 
> METHODS: Bacteremia episodes were considered persistent if there was a lack of clearance on day 4 while receiving ≥ 48 hours of active therapy and recurrent if there was clearance during hospitalization with a subsequent positive culture (collectively, recalcitrant bacteremia). A matched comparison group of nonrecalcitrant bacteremia patients was chosen in a 2:1 control to case ratio. Isolates were subjected to short- and long-read whole-genome sequencing. Hybrid assemblies were created using a custom pipeline.
> 
> RESULTS: A total of 46 recalcitrant infections from 41 patients were identified. Patients with persistent bacteremia were more often admitted to the intensive care unit upon admission relative to controls. Enterococcus faecalis strains causing persistent infections had a significantly higher proportion of genes associated with carbohydrate utilization relative to controls. Representation of functional groups associated with mutated genes was disparate between Enterococcus faecium and E. faecalis index and persistent isolates, suggesting species-specific adaptation.
> 
> DISCUSSION: Enterococcal isolates causing recalcitrant bacteremia were genomically diverse, indicating that strain-specific signatures are not drivers of persistence. However, comparisons of index versus persistent isolates revealed that E. faecium may be genetically preadapted to cause persistent infection, and site-specific structural variation during infection suggests the role of differential gene expression in adaptation and persistence. These data lay groundwork for future studies to define signatures of enterococcal adaptation during bacteremia.

> **中文摘要：**
> 背景：患有难治性肠球菌菌血症的患者面临更高的不良结局风险。我们在2016–2022年万古霉素耐药肠球菌菌血症结局研究（VENOUS）队列中，识别出经历难治性菌血症的患者，以进一步进行临床和基因组特征分析。
> 
> 方法：若在接受≥48小时的有效治疗后，第4天仍未清除菌血症，则定义为持续性；若住院期间血培养阴转后再度阳性，则定义为复发性（两者统称为难治性菌血症）。按照2:1的对照与病例比例，选择非难治性菌血症患者作为匹配对照。分离株接受短读长读联合全基因组测序，并采用定制流程生成混合组装序列。
> 
> 结果：共识别出来自41例患者的46次难治性感染。与对照组相比，持续性菌血症患者在入院时更常被收治入重症监护病房。引起持续感染的屎肠球菌株较对照菌株具有显著更高比例的碳水化合物代谢相关基因。与突变基因相关的功能群在屎肠球菌与粪肠球菌的初次分离株及持续感染株之间分布差异明显，提示存在物种特异的适应性。
> 
> 讨论：导致难治性菌血症的肠球菌分离株在基因组上表现出多样性，说明菌株特异性遗传标志并非持续感染的主要驱动因素。然而，初次与持续感染菌株的比较表明，粪肠球菌在遗传上可能预先具备引起持续感染的适应性，而感染过程中出现的特定位点结构变异则提示差异基因表达在适应与持续性中起作用。这些数据为未来阐明肠球菌在菌血症中适应性的特征奠定了基础。

### 第二部分 AI 大师评价

本研究通过多中心前瞻性队列分析，深入探讨了难治性肠球菌菌血症的临床表现与基因组特征。研究基于严格定义的持续性与复发性感染病例，结合全基因组长短读序列测定，揭示了物种间遗传适应性的差异。结果显示屎肠球菌在代谢基因方面的富集以及粪肠球菌的潜在遗传预适应性，为理解持续感染机制提供了线索。研究创新之处在于将基因组功能特征与临床表型相结合，但样本量有限及机制验证不足仍为后续工作的重点。

---

## 6. 在危重正位肝移植受者中达到激进药代动力学-药效学目标对持续输注β-内酰胺治疗早期移植后革兰阴性菌感染临床疗效的影响：一项为期三年的前瞻性观察研究的中期分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39854631)
**期刊：** The Journal of infectious diseases
**PMID：** 39854631
**DOI：** 10.1093/infdis/jiaf048

### 第一部分 原文与翻译

**英文原标题：** Impact of Attaining an Aggressive Pharmacokinetic-Pharmacodynamic Target on the Clinical Efficacy of Continuous Infusion β-Lactam Therapy for Early Posttransplant Gram-Negative Infections in Critically Ill Orthotopic Liver Transplant Recipients: An Interim Analysis of a 3-Year Prospective, Observational Study.

> **英文摘要：**
> BACKGROUND: To assess the impact of attaining aggressive β-lactam (BL) pharmacokinetic-pharmacodynamic (PK/PD) targets on clinical efficacy in critically ill orthotopic liver transplant (OLT) recipients with documented early gram-negative infections.
> 
> METHODS: The study prospectively enrolled OLT recipients admitted to the posttransplant intensive care unit between June 2021 and May 2024; they had documented gram-negative infections treated with targeted therapy continuous infusion (CI) BLs and underwent therapeutic drug monitoring (TDM)-guided BL dosing adjustment within the first 72 hours. Aggressive PK/PD target attainment was measured. Multivariate logistic regression analyses were performed to test independent variables associated with 30-day resistance occurrence.
> 
> RESULTS: Fifty critically ill OLT recipients were treated with CI BL in monotherapy (n = 34) or combination (n = 16) therapy for documented gram-negative infections No significant difference in clinical/microbiological outcome emerged between monotherapy and combination therapy. In 4 patients (8.0%), resistance developed within 30 days. At multivariate analysis, failure in attaining an aggressive BL PK/PD target emerged as the only independent predictor of 30-day resistance development (odds ratio, 14.33 [95% confidence interval, 1.46-140.53]; P = .02).
> 
> CONCLUSIONS: Attaining an aggressive PK/PD target with CI BLs in critically ill OLT recipients with documented gram-negative infections could represent an effective strategy for minimizing resistance occurrence to the selected BL.

> **中文摘要：**
> 背景：旨在评估在危重正位肝移植（OLT）受者中达到激进β-内酰胺（BL）药代动力学-药效学（PK/PD）目标，对其早期明确的革兰阴性菌感染临床疗效的影响。
> 
> 方法：本研究前瞻性纳入2021年6月至2024年5月期间入住移植后重症监护病房的OLT受者；这些患者均确诊为革兰阴性菌感染，并接受靶向治疗的持续输注（CI）BL，同时在前72小时内进行治疗药物监测（TDM）指导的BL剂量调整。测定达成激进PK/PD目标的比例。采用多变量Logistic回归分析评估与30天内耐药发生相关的独立变量。
> 
> 结果：共50例危重OLT受者接受CI BL单药（n=34）或联合治疗（n=16）以应对确诊的革兰阴性菌感染。单药与联合治疗间在临床和微生物学结局上无显著差异。4例患者（8.0%）于30天内出现耐药。在多变量分析中，未能达到激进BL PK/PD目标被确认为30天耐药发生的唯一独立预测因子（比值比14.33，95%置信区间1.46-140.53；P = 0.02）。
> 
> 结论：在危重OLT受者中，对于确诊的革兰阴性菌感染，通过CI BL达到激进PK/PD目标可能是一种有效减少所选BL耐药发生的策略。

### 第二部分 AI 大师评价

该研究以危重正位肝移植受者为对象，探讨持续输注β-内酰胺达到激进PK/PD目标对早期革兰阴性菌感染疗效及耐药风险的影响。研究采用前瞻性设计并结合TDM指导剂量调整，分析结果显示未达标是30天耐药的独立预测因素。该结果提示强化β-内酰胺暴露可能有助于减少耐药风险，为重症移植患者抗菌剂个体化管理提供了循证依据。尽管为中期分析，样本量有限，但研究设计严谨、临床相关性强。

---

## 7. 评估因呼吸道合胞病毒相关危重疾病住院婴儿的临床改善情况

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/39812486)
**期刊：** The Journal of infectious diseases
**PMID：** 39812486
**DOI：** 10.1093/infdis/jiaf018

### 第一部分 原文与翻译

**英文原标题：** Assessing Clinical Improvement of Infants Hospitalized for Respiratory Syncytial Virus-Related Critical Illness.

> **英文摘要：**
> BACKGROUND: Pediatric respiratory syncytial virus (RSV)-related acute lower respiratory tract infection (LRTI) commonly requires hospitalization. The Clinical Progression Scale-Pediatrics (CPS-Ped) measures level of respiratory support and degree of hypoxia across a range of disease severity, but it has not been applied in infants hospitalized with severe RSV-LRTI.
> 
> METHODS: We analyzed data from a prospective surveillance registry of infants hospitalized for RSV-related complications across 39 pediatric intensive care units in the United States from October through December 2022. We assigned CPS-Ped (0 = discharged home at respiratory baseline to 8 = death) at admission and days 2-7, 10, and 14. We identified predictors of clinical improvement (CPS-Ped ≤2 or 3-point decrease) by day 7 using multivariable log-binomial regression models and estimated the sample size (80% power) to detect 15% between-group clinical improvement with CPS-Ped versus hospital length of stay (LOS).
> 
> RESULTS: Of 585 hospitalized infants, 138 (23.6%) received invasive mechanical ventilation (IMV) and 1 died. Failure to clinically improve by day 7 occurred in 205 (35%) infants and was associated with age <3 months, prematurity, underlying respiratory condition, and IMV in the first 24 hours in the multivariable analysis. The estimated sample size per arm required for detecting a 15% clinical improvement in a potential study was 584 using CPS-Ped clinical improvement versus 2031 for hospital LOS.
> 
> CONCLUSIONS: CPS-Ped can be used to capture a range of disease severity and track clinical improvement in infants who develop RSV-related critical illness and could be useful for evaluating therapeutic interventions for RSV.

> **中文摘要：**
> 背景：儿童呼吸道合胞病毒（RSV）相关的急性下呼吸道感染（LRTI）常需住院治疗。儿科临床进展量表（CPS-Ped）可用于评估不同疾病严重程度下的呼吸支持水平和缺氧程度，但尚未应用于因重度RSV-LRTI住院的婴儿中。
> 
> 方法：我们分析了2022年10月至12月间，美国39家儿科重症监护病房中因RSV相关并发症住院婴儿的前瞻性监测登记数据。我们在入院时及第2–7、10、14天赋予CPS-Ped评分（0 = 呼吸状态恢复至基础并出院，8 = 死亡）。利用多变量对数二项回归模型，我们在第7天辨识临床改善（CPS-Ped ≤2或下降≥3分）的预测因素，并估算基于CPS-Ped与住院时间（LOS）比较，检测组间15%临床改善差异所需的样本量（检出效能80%）。
> 
> 结果：在585名住院婴儿中，138名（23.6%）接受了有创机械通气（IMV），1名死亡。205名（35%）婴儿至第7天未见临床改善，多变量分析显示，其与年龄<3个月、早产、基础呼吸系统疾病以及入院后前24小时内使用IMV相关。若要在潜在研究中检测15%的临床改善差异，采用CPS-Ped评估所需的每组样本量为584人，而以住院时间为指标则需2031人。
> 
> 结论：CPS-Ped可用于反映RSV相关危重疾病婴儿的病情严重程度变化并追踪临床改善，有助于评估RSV治疗干预的疗效。

### 第二部分 AI 大师评价

本研究旨在验证儿科临床进展量表（CPS-Ped）在评估RSV相关危重症婴儿临床改善中的可行性与敏感性。研究基于美国多中心前瞻性监测数据，通过CPS-Ped评分动态评估疾病严重度及改善趋势，并确定关键预后因素。结果显示CPS-Ped较传统住院时间指标在评价疗效时更具效率和统计能力。该研究为未来RSV治疗干预研究提供了一种更科学的病情评估工具，但其结论仍需在不同地区和人群中进一步验证。

---

速递结束，祝您工作愉快！